BayCom (BCML) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Reported Q4 2024 net income of $6.1 million ($0.55 per diluted share), up 1.7% sequentially but down 4.3% year-over-year; full-year 2024 net income was $23.6 million ($2.10 per diluted share), a 13.9% decrease from 2023.
Net interest margin improved to 3.80% in Q4 2024 from 3.73% in Q3 2024, but slightly below 3.86% in Q4 2023.
Credit quality improved with a reversal of provision for credit losses and lower nonperforming loans.
Management remains optimistic for 2025, citing strong financial condition and continued lending demand.
Financial highlights
Q4 2024 net interest income rose 3.1% sequentially to $23.6 million; up 0.2% year-over-year.
Noninterest income dropped sharply to $87,000 in Q4 2024 from $2.7 million in both Q3 2024 and Q4 2023, mainly due to negative fair value adjustments on equity securities.
Noninterest expense was $16.0 million in Q4 2024, down 0.6% sequentially but up 6.0% year-over-year, driven by higher salaries and benefits.
Q4 2024 provision for income taxes was $1.9 million, down 13.5% sequentially and 18.2% year-over-year, with an effective tax rate of 24.3%.
Allowance for credit losses for loans was $17.9 million (0.92% of loans) at year-end, down from $22.0 million (1.14%) a year ago.
Outlook and guidance
Management expects continued lending demand and improving bank valuations in 2025.
Commitment to enhancing shareholder value through share repurchases and dividends.
Latest events from BayCom
- Q4 2025 earnings grew 37% sequentially on higher net interest income and lower credit loss provisions.BCML
Q4 202522 Jan 2026 - Director elections, say-on-pay, and auditor ratification headline a governance-focused agenda.BCML
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, executive pay, and auditor, with online proxy access.BCML
Proxy Filing2 Dec 2025 - Earnings declined on higher credit loss provisions, but capital and liquidity remain strong.BCML
Q3 20257 Nov 2025 - Q2 2024 net income fell 22% as margins compressed, but capital and deposits remained strong.BCML
Q2 202414 Oct 2025 - Earnings and net interest margin improved, with robust capital and higher nonperforming loans.BCML
Q2 202511 Aug 2025 - Q3 net loss widened to $16.8M; $182.2M cash on hand supports clinical pipeline into 2027.BCML
Q3 202413 Jun 2025 - Q1 2025 net income was $5.7M, with margin gains and robust capital ratios despite higher provisions.BCML
Q1 20256 Jun 2025